The Latin America, Middle East and Africa Clinical Risk Grouping Solution Market would witness market growth of 14.9% CAGR during the forecast period (2024-2031).
The Brazil market dominated the LAMEA Clinical Risk Grouping Solution Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $27.7 million by 2031. The Argentina market is showcasing a CAGR of 15.6% during 2024-2031. Additionally, the UAE market would register a CAGR of 13.9% during 2024-2031.
the application of clinical risk grouping in personalized medicine extends beyond oncology. In areas such as cardiology, endocrinology, and neurology, these solutions are used to develop personalized treatment plans that address patients' specific risks and needs.
Moreover, in cardiology, a patient with a genetic predisposition to heart disease might be monitored more closely and prescribed preventive measures, such as lifestyle changes or medications, to reduce their risk of developing serious cardiovascular conditions. In diabetes management, clinical risk grouping can assist in the identification of patients who are at a higher risk of complications.
The necessity for sophisticated instruments to improve patient care, optimize resource allocation, and reduce healthcare costs is increasingly acknowledged as healthcare systems in LAMEA continue to develop. In Brazil, the rising prevalence of chronic diseases significantly drives the demand for clinical risk grouping solutions. According to the Brazilian Ministry of Health, chronic diseases such as diabetes, hypertension, and cardiovascular conditions are leading causes of death in the country, affecting millions of Brazilians. Brazilian healthcare providers increasingly adopt clinical risk grouping solutions to combat this growing health crisis and better identify high-risk patients.
The Brazil market dominated the LAMEA Clinical Risk Grouping Solution Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $27.7 million by 2031. The Argentina market is showcasing a CAGR of 15.6% during 2024-2031. Additionally, the UAE market would register a CAGR of 13.9% during 2024-2031.
the application of clinical risk grouping in personalized medicine extends beyond oncology. In areas such as cardiology, endocrinology, and neurology, these solutions are used to develop personalized treatment plans that address patients' specific risks and needs.
Moreover, in cardiology, a patient with a genetic predisposition to heart disease might be monitored more closely and prescribed preventive measures, such as lifestyle changes or medications, to reduce their risk of developing serious cardiovascular conditions. In diabetes management, clinical risk grouping can assist in the identification of patients who are at a higher risk of complications.
The necessity for sophisticated instruments to improve patient care, optimize resource allocation, and reduce healthcare costs is increasingly acknowledged as healthcare systems in LAMEA continue to develop. In Brazil, the rising prevalence of chronic diseases significantly drives the demand for clinical risk grouping solutions. According to the Brazilian Ministry of Health, chronic diseases such as diabetes, hypertension, and cardiovascular conditions are leading causes of death in the country, affecting millions of Brazilians. Brazilian healthcare providers increasingly adopt clinical risk grouping solutions to combat this growing health crisis and better identify high-risk patients.
List of Key Companies Profiled
- Conduent, Incorporated
- 3M Company
- Oracle Corporation (Cerner Corporation)
- Microsoft Corporation (Nuance Communications, Inc.)
- Health Catalyst, Inc.
- Koninklijke Philips N.V.
- Siemens Healthineers AG (Siemens AG)
- HBI Solutions
- Lightbeam Health Solutions
- Reveleer
Market Report Segmentation
By Product
- Software
- Services
By End-use
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Long Term Care Centers
- Other
By Deployment
- Private Cloud
- Public Cloud
- Hybrid Cloud
By Application
- Population Health Management
- Chronic Disease Management
- Clinical Decision Support
- Fraud Detection and Prevention
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. LAMEA Clinical Risk Grouping Solution Market by Product
Chapter 6. LAMEA Clinical Risk Grouping Solution Market by End-use
Chapter 7. LAMEA Clinical Risk Grouping Solution Market by Deployment
Chapter 8. LAMEA Clinical Risk Grouping Solution Market by Application
Chapter 9. LAMEA Clinical Risk Grouping Solution Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Conduent, Incorporated
- 3M Company
- Oracle Corporation (Cerner Corporation)
- Microsoft Corporation (Nuance Communications, Inc.)
- Health Catalyst, Inc.
- Koninklijke Philips N.V.
- Siemens Healthineers AG (Siemens AG)
- HBI Solutions
- Lightbeam Health Solutions
- Reveleer
Methodology
LOADING...
